The re-opened comment period for feedback to the US Food and Drug Administration on direct-to-consumer genetic testing ends today. The panel focused on molecular and clinical genetics, which is part of the medical devices committee, is seeking “input and comments from interested stakeholders to discuss scientific issues concerning DTC tests,” according to the Federal Register.